, Volume 75, Issue 15, pp 1725–1738 | Cite as

Management of Hematologic Malignancies: Special Considerations in Pregnant Women

  • Odelia Amit
  • Merav Barzilai
  • Irit Avivi
Therapy in Practice


The diagnosis and management of hematologic malignancy during pregnancy is a significant challenge. This is due to both medical and ethical considerations regarding when and how to treat this special sub-group of patients. Recurring uncertainties remain around appropriate imaging techniques, timing and dosage of chemotherapy, and timing of delivery. In this article we examine and summarize current literature in this field to assist physicians in their understanding and management of this patient group. Special attention has been given to diagnostic and staging procedures, risks associated with chemotherapy at different stages of gestation, and chemotherapy-dose adaption during pregnancy. In addition, recommended guidelines for management of lymphoma, leukemia, and planning delivery are discussed. A multidisciplinary team approach is critical for patient care, as is shared decision making with the patient and family.


Acute Myeloid Leukemia Imatinib Chronic Myeloid Leukemia Hematologic Malignancy Nilotinib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards


The preparation of this review received no funding.

Conflict of interest

O. Amit, M. Barzilai, and I. Avivi have no conflicts of interest to declare.


  1. 1.
    Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45(1):8–30. Accessed 9 Nov 2014.
  2. 2.
    Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. Eur J Cancer. 2006;42(2):126–40. doi: 10.1016/j.ejca.2005.10.014.CrossRefPubMedGoogle Scholar
  3. 3.
    Lavi N, Horowitz NA, Brenner B. An update on the management of hematologic malignancies in pregnancy. Womens Health (Lond Engl). 2014;10(3):255–66. doi: 10.2217/whe.14.17.CrossRefPubMedGoogle Scholar
  4. 4.
    Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V. Cancer chemotherapy and pregnancy. J Obstet Gynaecol Can. 2013;35(3):263–280. Accessed 1 Aug 2015.
  5. 5.
    Briggs GG, Freeman RK YS. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk, vol 9th ed. Philadelphia: Wolters Kluwer/Williams & Wilkins; 2011.Google Scholar
  6. 6.
    Chen MM, Coakley FV, Kaimal A, Laros RK. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112(2 Pt 1):333–40. doi: 10.1097/AOG.0b013e318180a505.CrossRefPubMedGoogle Scholar
  7. 7.
    Lynch CM, Sinnott JT, Holt DA, Herold AH. Use of antibiotics during pregnancy. Am Fam Physician. 1991;43(4):1365–1368. Accessed 19 Mar 2015.
  8. 8.
    Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70. doi: 10.1200/JCO.2010.31.8436.CrossRefPubMedGoogle Scholar
  9. 9.
    Shapira T, Pereg D, Lishner M. How i treat acute and chronic leukemia in pregnancy. Blood Rev. 2008;22(5):247–59. doi: 10.1016/j.blre.2008.03.006.CrossRefPubMedGoogle Scholar
  10. 10.
    Leslie KK, Koil C, Rayburn WF. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin N Am. 2005;32(4):627–40. doi: 10.1016/j.ogc.2005.08.009.CrossRefGoogle Scholar
  11. 11.
    Kevric J, Nair S, Ernest D. Delayed recognition of a rare mediastinal lymphoma presenting as postpartum circulatory collapse. Case Rep Obstet Gynecol. 2014;2014:415352. doi: 10.1155/2014/415352.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Lees CC, Tsirigotis M, Carr JV, Richards MA. T cell non-Hodgkin’s lymphoma presenting in the first trimester of pregnancy. Postgrad Med J. 1994;70(823):371–372. Accessed 13 Nov 2014.
  13. 13.
    Avivi I, Farbstein D, Brenner B, Horowitz NA. Non-Hodgkin lymphomas in pregnancy: tackling therapeutic quandaries. Blood Rev. 2014;28(5):213–20. doi: 10.1016/j.blre.2014.06.004.CrossRefPubMedGoogle Scholar
  14. 14.
    Pereg D, Koren G, Lishner M. The treatment of Hodgkin’s and non-Hodgkin’s lymphoma in pregnancy. Haematologica. 2007;92(9):1230–7. doi: 10.3324/haematol.11097.CrossRefPubMedGoogle Scholar
  15. 15.
    Weisz B, Meirow D, Schiff E, Lishner M. Impact and treatment of cancer during pregnancy. Expert Rev Anticancer Ther. 2004;4(5):889–902. doi: 10.1586/14737140.4.5.889.CrossRefPubMedGoogle Scholar
  16. 16.
    Mauch PM, Kalish LA, Kadin M, Coleman CN, Osteen R, Hellman S. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer. 1993;71(6):2062–2071. Accessed 6 Mar 2015.
  17. 17.
    Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist. 2002;7(4):279–87.PubMedGoogle Scholar
  18. 18.
    Stensheim H, Møller B, van Dijk T, Fosså SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol. 2009;27(1):45–51. doi: 10.1200/JCO.2008.17.4110.CrossRefPubMedGoogle Scholar
  19. 19.
    Evens AM, Advani R, Press OW, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol. 2013;31(32):4132–9. doi: 10.1200/JCO.2013.49.8220.CrossRefPubMedGoogle Scholar
  20. 20.
    Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer. 1982;50(12):2699–2707. Accessed 6 Mar 2015.
  21. 21.
    Vandenbriele C, Dierickx D, Amant F, Delforge M. The treatment of hematologic malignancies in pregnancy. Facts, views Vis ObGyn. 2010;2(2):74–87. Accessed 8 Nov 2014.
  22. 22.
    Rizack T, Mega A, Legare R, Castillo J. Management of hematological malignancies during pregnancy. Am J Hematol. 2009;84(12):830–41. doi: 10.1002/ajh.21547.CrossRefPubMedGoogle Scholar
  23. 23.
    Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75(1):4–9. Accessed 6 Mar 2015.
  24. 24.
    Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. Am J Hematol. 1999;61(1):10–15. Accessed 6 Mar 2015.
  25. 25.
    Rovera F, Frattini F, Coglitore A, et al. Breast cancer in pregnancy. Breast J. 2010;16(Suppl 1):S22–S25. doi: 10.1111/j.1524-4741.2010.00998.x.
  26. 26.
    Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014. doi: 10.1200/JCO.2013.54.8800.PubMedCentralGoogle Scholar
  27. 27.
    Martin DD. Review of radiation therapy in the pregnant cancer patient. Clin Obstet Gynecol. 2011;54(4):591–601. doi: 10.1097/GRF.0b013e318236e935.CrossRefPubMedGoogle Scholar
  28. 28.
    Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005;6(5):328–33. doi: 10.1016/S1470-2045(05)70169-8.CrossRefPubMedGoogle Scholar
  29. 29.
    Colletti PM. PET-CT in the pregnant patient. Am Coll Radiol. 2012. Accessed 17 Mar 2015.
  30. 30.
    Russell JR, Stabin MG, Sparks RB. Placental transfer of radiopharmaceuticals and dosimetry in pregnancy. Health Phys. 1997;73(5):747–755. Accessed 17 Mar 2015.
  31. 31.
    Stabin MG. Proposed addendum to previously published fetal dose estimate tables for 18F-FDG. J Nucl Med. 2004;45(4):634–635. Accessed 17 Mar 2015.
  32. 32.
    Zanotti-Fregonara Paolo, Jan Sebastien, Taieb David, Cammilleri Serge, Trebossen Regine, Hindie Elif, Mundle OM. Absorbed 18F-FDG dose to the fetus during early pregnancy. J Nucl Med. 2010;51:803–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Brent RL. The effect of embryonic and fetal exposure to X-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol. 1989;16(5):347–368. Accessed 4 Dec 2014.
  34. 34.
    Austin LM, Frush DP. Compendium of national guidelines for imaging the pregnant patient. AJR Am J Roentgenol. 2011;197(4):W737–46. doi: 10.2214/AJR.10.6351.CrossRefPubMedGoogle Scholar
  35. 35.
    Shellock FG, Kanal E. Policies, guidelines, and recommendations for MR imaging safety and patient management. SMRI Safety Committee. J Magn Reson Imaging. 1991;1(1):97–101. Accessed 4 Dec 2014.
  36. 36.
    Bulas D, Egloff A. Benefits and risks of MRI in pregnancy. Semin Perinatol. 2013;37(5):301–4. doi: 10.1053/j.semperi.2013.06.005.CrossRefPubMedGoogle Scholar
  37. 37.
    Sundgren PC, Leander P. Is administration of gadolinium-based contrast media to pregnant women and small children justified? J Magn Reson Imaging. 2011;34(4):750–7. doi: 10.1002/jmri.22413.CrossRefPubMedGoogle Scholar
  38. 38.
    Mühler MR, Clément O, Salomon LJ, et al. Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice. Radiology. 2011;258(2):455–60. doi: 10.1148/radiol.10100652.CrossRefPubMedGoogle Scholar
  39. 39.
    FDA Pregnancy Categories A, B, C, D, X, N Explained. Accessed 1 Aug 2015.
  40. 40.
    Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283–91. doi: 10.1016/S1470-2045(04)01466-4.CrossRefPubMedGoogle Scholar
  41. 41.
    Wagner VM, Hill JS, Weaver D, Baehner RL. Congenital abnormalities in baby born to cytarabine treated mother. Lancet. 1980;2(8185):98–99. Accessed 3 Jan 2015.
  42. 42.
    Reynoso EE, Keating A, Baker MA. Acute leukemia occurring 19 years after treatment of acute lymphoblastic leukemia. Cancer. 1987;59(11):1963–1965. Accessed 10 Nov 2014.
  43. 43.
    Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28(4):683–9. doi: 10.1200/JCO.2009.23.2801.CrossRefPubMedGoogle Scholar
  44. 44.
    Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012;13(9):887–96. doi: 10.1016/S1470-2045(12)70261-9.CrossRefPubMedGoogle Scholar
  45. 45.
    Abdel-Hady E-S, Hemida RA-H, Gamal A, El-Zafarany M, Toson E, El-Bayoumi MA. Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy. Arch Gynecol Obstet. 2012;286(2):283–6. doi: 10.1007/s00404-012-2287-5.CrossRefGoogle Scholar
  46. 46.
    Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13(3):256–64. doi: 10.1016/S1470-2045(11)70363-1.CrossRefPubMedGoogle Scholar
  47. 47.
    Van Calsteren K, Amant F. Chemotherapy during pregnancy: pharmacokinetics and -impact on foetal neurological development. Facts, views Vis ObGyn. 2010;2(4):278–286. Accessed 20 Oct 2014.
  48. 48.
    Van Calsteren K, Verbesselt R, Beijnen J, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol. 2010;119(3):594–600. doi: 10.1016/j.ygyno.2010.08.019.CrossRefPubMedGoogle Scholar
  49. 49.
    Wiebe VJ, Sipila PEH. Pharmacology of antineoplastic agents in pregnancy. Crit Rev Oncol Hematol. 1994;16(2):75–112. doi: 10.1016/1040-8428(94)90043-4.CrossRefPubMedGoogle Scholar
  50. 50.
    Van Hasselt JGC, van Calsteren K, Heyns L, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol. 2014;25(10):2059–65. doi: 10.1093/annonc/mdu140.CrossRefPubMedGoogle Scholar
  51. 51.
    Avilés A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001;2(3):173–177. Accessed 20 Oct 2014.
  52. 52.
    Avilés A, Neri N, Nambo M-J. Hematological malignancies and pregnancy: treat or no treat during first trimester. Int J Cancer. 2012;131(11):2678–83. doi: 10.1002/ijc.27560.CrossRefPubMedGoogle Scholar
  53. 53.
    Koren G, LMSS, editors. The Motherisk guide to cancer in pregnancy and lactation. 2nd ed. Toronto: Motherisk Program; 2005.Google Scholar
  54. 54.
    Avilés A, Díaz-Maqueo JC, Talavera A, Guzmán R, García EL. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol. 1991;36(4):243–248. Accessed 10 Nov 2014.
  55. 55.
    Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. Lancet. 2012;379(9815):580–7. doi: 10.1016/S0140-6736(11)61348-2.CrossRefPubMedGoogle Scholar
  56. 56.
    Voulgaris E, Pentheroudakis G, Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg Oncol. 2011;20(4):e175–85. doi: 10.1016/j.suronc.2011.06.002.CrossRefPubMedGoogle Scholar
  57. 57.
    Rosenzweig AI, Crews QE, Hopwood HG. Vinblastine sulfate in Hodgkin’s disease in pregnancy. Ann Intern Med. 1964;61:108–112. Accessed 6 Dec 2014.
  58. 58.
    Connors JM. Challenging problems: coincident pregnancy, HIV infection, and older age. Hematology Am Soc Hematol Educ Program. 2008:334–339. doi: 10.1182/asheducation-2008.1.334.
  59. 59.
    Armstrong JG, Dyke RW, Fouts PJ. Vinblastine sulfate treatment of Hodgkin’s disease during a pregnancy. Science. 1964;143(3607):703. Accessed 9 Aug 2015.
  60. 60.
    Lacher MJ. Use of vinblastine sulfate to treat Hodgkin’s disease during pregnancy. Ann Intern Med. 1964;61:113–115. Accessed 9 Aug 2015.
  61. 61.
    Abadi U, Koren G, Lishner M. Leukemia and lymphoma in pregnancy. Hematol Oncol Clin N Am. 2011;25(2):277–291 (vii). doi: 10.1016/j.hoc.2011.01.001.
  62. 62.
    Antonelli NM, Dotters DJ, Katz VL, Kuller JA. Cancer in pregnancy: a review of the literature. Part I. Obstet Gynecol Surv. 1996;51(2):125–134. Accessed 10 Nov 2014.
  63. 63.
    Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70(11):1445–76. doi: 10.2165/11201110-000000000-00000.CrossRefPubMedGoogle Scholar
  64. 64.
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42. doi: 10.1056/NEJMoa011795.CrossRefPubMedGoogle Scholar
  65. 65.
    Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell. Blood. 2004;104(10):3064–71. doi: 10.1182/blood-2004-04-1323.CrossRefPubMedGoogle Scholar
  66. 66.
    Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–506. doi: 10.1182/blood-2010-07-295444.CrossRefPubMedGoogle Scholar
  67. 67.
    Sarno MA, Mancari R, Azim HA, Colombo N, Peccatori FA. Are monoclonal antibodies a safe treatment for cancer during pregnancy? Immunotherapy. 2013;5(7):733–41. doi: 10.2217/imt.13.64.CrossRefPubMedGoogle Scholar
  68. 68.
    Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol. 2004;72(4):292–5. doi: 10.1111/j.1600-0609.2004.00214.x.CrossRefPubMedGoogle Scholar
  69. 69.
    National Center on Birth Defects and Developmental Disabilities Home|NCBDDD|CDC. Accessed 22 Nov 2014.
  70. 70.
    Ojeda-Uribe M, Gilliot C, Jung G, Drenou B, Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol. 2006;26(4):252–5. doi: 10.1038/ Scholar
  71. 71.
    Azim HA, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6(6):821–6. doi: 10.1586/eci.10.77.CrossRefPubMedGoogle Scholar
  72. 72.
    Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909–20. doi: 10.1136/ard.2010.144998.PubMedCentralCrossRefPubMedGoogle Scholar
  73. 73.
    Østensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009;5(7):382–90. doi: 10.1038/nrrheum.2009.103.CrossRefPubMedGoogle Scholar
  74. 74.
    Koren G, Weiner L, Lishner M, Zemelickes D, Finegen J. Cancer in pregnancy: identification of unanswered questions on maternal and fetal risks. Obstet Gynecol Surv. 1990;45(8):509–514. Accessed 13 Nov 2014.
  75. 75.
    Spitzer M, Citron M, Ilardi CF, Saxe B. Non-Hodgkin’s lymphoma during pregnancy. Gynecol Oncol. 1991;43(3):309–312. Accessed 13 Nov 2014.
  76. 76.
    Fenig E, Mishaeli M, Kalish Y, Lishner M. Pregnancy and radiation. Cancer Treat Rev. 2001;27(1):1–7. doi: 10.1053/ctrv.2000.0193.CrossRefPubMedGoogle Scholar
  77. 77.
    Silva PT, de Almeida HM, Príncipe F, Pereira-Leite L. Non-Hodgkin lymphoma during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1998;77(2):249–251. Accessed 13 Nov 2014.
  78. 78.
    Reimer P, Rüdiger T, Müller J, Rose C, Wilhelm M, Weissinger F. Subcutaneous panniculitis-like T-cell lymphoma during pregnancy with successful autologous stem cell transplantation. Ann Hematol. 2003;82(5):305–9. doi: 10.1007/s00277-003-0647-8.PubMedGoogle Scholar
  79. 79.
    Bhele S, Gujral S. Bilateral peripheral T-cell lymphoma of breast: a case report. Indian J Pathol Microbiol. 2007;50(4):816–818. Accessed 13 Nov 2014.
  80. 80.
    Zuazu J, Julia A, Sierra J, et al. Pregnancy outcome in hematologic malignancies. Cancer. 1991;67(3):703–709. Accessed 13 Nov 2014.
  81. 81.
    Peres RM, Sanseverino MT, Guimarães JL, et al. Assessment of fetal risk associated with exposure to cancer chemotherapy during pregnancy: a multicenter study. Braz J Med Biol Res. 2001;34(12):1551–1559. Accessed 13 Nov 2014.
  82. 82.
    Guven S, Ozcebe OI, Tuncer ZS. Non-Hodgkin’s lymphoma complicating pregnancy: a case report. Eur J Gynaecol Oncol. 2005;26(4):457–458. Accessed 13 Nov 2014.
  83. 83.
    Lishner M, Zemlickis D, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Maternal and foetal outcome following Hodgkin’s disease in pregnancy. Br J Cancer. 1992;65(1):114–117. Accessed 20 Oct 2014.
  84. 84.
    Warkany J. Aminopterin and methotrexate: folic acid deficiency. Teratology. 1978;17(3):353–7. doi: 10.1002/tera.1420170314.CrossRefPubMedGoogle Scholar
  85. 85.
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–2795. Accessed 3 Mar 2015.
  86. 86.
    Luminari S, Bellei M, Biasoli I, Federico M. Follicular lymphoma-treatment and prognostic factors. Rev Bras Hematol Hemoter. 2012;34(1):54–9. doi: 10.5581/1516-8484.20120015.PubMedCentralCrossRefPubMedGoogle Scholar
  87. 87.
    Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–522. Accessed 3 Dec 2014.
  88. 88.
    Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–1117. Accessed 3 Dec 2014.
  89. 89.
    NCCNclinical practice guidelines in oncology.Non-Hodgkin’s Lymphomas. Version 1. 2013. Accessed 13 Nov 2014.
  90. 90.
    Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24(3):561–76. doi: 10.1093/annonc/mds517.CrossRefPubMedGoogle Scholar
  91. 91.
    De Santis M, Lucchese A, De Carolis S, Ferrazani S, Caruso A. Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. Eur J Cancer Care (Engl). 2000;9(4):235–237. Accessed 3 Jan 2015.
  92. 92.
    Wagner LK AK. American College of Radiology. ACR practice guideline for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. Pract Guidel Tech Stand. Reston: Am Coll Radiol; 2008 (resolution).Google Scholar
  93. 93.
    Ebert U, Löffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997;74(2):207–220. Accessed 3 Jan 2015.
  94. 94.
    Schafer AI. Teratogenic effects of antileukemic chemotherapy. Arch Intern Med. 1981;141(4):514–515. Accessed 3 Jan 2015.
  95. 95.
    Henig I, Vidal L, Henig O, Benyamini N AI. Paper: acute myeloid leukemia diagnosed during pregnancy: facing challenges. Systematic review and analysis of 174 reported cases. Accessed 6 Mar 2015.
  96. 96.
    Dekrem J, Van Calsteren K, Amant F. Effects of fetal exposure to maternal chemotherapy. Paediatr Drugs. 2013;15(5):329–34. doi: 10.1007/s40272-013-0040-6.CrossRefPubMedGoogle Scholar
  97. 97.
    Matsuo K, Shimoya K, Ueda S, Wada K, Koyama M, Murata Y. Idarubicin administered during pregnancy: its effects on the fetus. Gynecol Obstet Invest. 2004;58(4):186–8. doi: 10.1159/000079814.CrossRefPubMedGoogle Scholar
  98. 98.
    Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med. 1992;152(3):573–576. Accessed 9 Nov 2014.
  99. 99.
    Chrisomalis L, Baxi L, Heller D. Chronic lymphocytic leukemia in pregnancy. Am J Obstet Gynecol. 1996;175(5):1381–2. doi: 10.1016/S0002-9378(96)70062-5.CrossRefPubMedGoogle Scholar
  100. 100.
    Turchi JJ, Villasis C. Anthracyclines in the treatment of malignancy in pregnancy. Cancer. 1988;61(3):435–440. Accessed 3 Jan 2015.
  101. 101.
    Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32. doi: 10.1182/blood-2011-01-293050.PubMedCentralCrossRefPubMedGoogle Scholar
  102. 102.
    Breccia M, Cimino G, Alimena G, De Carolis S, Lo Coco F, Mandelli F. AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation. Haematologica. 2002;87(2):ELT12. Accessed 3 Jan 2015.
  103. 103.
    Siu BL, Alonzo MR, Vargo TA, Fenrich AL. Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy. Int J Gynecol Cancer. 12(4):399–402. Accessed 3 Jan 2015.
  104. 104.
    Celo JS, Kim HC, Houlihan C, Canavan BF, Manzullo GP, Saidi P. Acute promyelocytic leukemia in pregnancy: all-trans retinoic acid as a newer therapeutic option. Obstet Gynecol. 1994;83(5 Pt 2):808–811. Accessed 3 Jan 2015.
  105. 105.
    Delgado-Lamas JL, Garcés-Ruiz OM. Malignancy: case report: acute promyelocytic leukemia in late pregnancy. Successful treatment with all-trans-retinoic acid (ATRA) and chemotherapy. Hematology. 2000;4(5):415–418. Accessed 3 Jan 2015.
  106. 106.
    Harrison P, Chipping P, Fothergill GA. Successful use of all-trans retinoic acid in acute promyelocytic leukaemia presenting during the second trimester of pregnancy. Br J Haematol. 1994;86(3):681–682. Accessed 3 Jan 2015.
  107. 107.
    Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–91. doi: 10.1182/blood-2008-04-150250.CrossRefPubMedGoogle Scholar
  108. 108.
    Hahn KME, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107(6):1219–26. doi: 10.1002/cncr.22081.CrossRefPubMedGoogle Scholar
  109. 109.
    Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21. doi: 10.1056/NEJMoa1300874.CrossRefPubMedGoogle Scholar
  110. 110.
    Environmental Protection Agency. US Environmental Protection Agency. Accessed 7 Mar 2015.
  111. 111.
    De Vita VT, Hellman S, SAR, editors. Cancer, principles and practice of oncology (7th ed.). Philadelphia: Lippincot Williams & Wilkins;0 2001. p. 2121.Google Scholar
  112. 112.
    Mesquita MM, Pestana A, Mota A. Successful pregnancy occurring with interferon-alpha therapy in chronic myeloid leukemia. Acta Obstet Gynecol Scand. 2005;84(3):300–1. doi: 10.1111/j.0001-6349.2005.0358b.x.CrossRefPubMedGoogle Scholar
  113. 113.
    Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505–8. doi: 10.1182/blood-2007-10-114900.CrossRefPubMedGoogle Scholar
  114. 114.
    Milojkovic D, Apperley JF. How I treat leukemia during pregnancy. Blood. 2014;123(7):974–84. doi: 10.1182/blood-2013-08-283580.CrossRefPubMedGoogle Scholar
  115. 115.
    Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs. 2012;23(7):754–7. doi: 10.1097/CAD.0b013e328352a8fe.CrossRefPubMedGoogle Scholar
  116. 116.
    Ault P, Kantarjian H, O’Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24(7):1204–8. doi: 10.1200/JCO.2005.04.6557.CrossRefPubMedGoogle Scholar
  117. 117.
    Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–22. doi: 10.1182/blood-2013-02-483750.CrossRefPubMedGoogle Scholar
  118. 118.
    Cortes J, O’Brien S, Ault P, et al. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. ASH Annu Meet Abstr. 2008;112(11):3230. Accessed 18 Mar 2015.
  119. 119.
    Thauvin-Robinet C, Maingueneau C, Robert E, et al. Exposure to hydroxyurea during pregnancy: a case series. Leukemia. 2001;15(8):1309–1311. Accessed 7 Mar 2015.
  120. 120.
    Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012;33(3):265–268. doi: 10.1016/j.reprotox.2011.11.003.
  121. 121.
    Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51. doi: 10.1182/blood-2009-03-209262.CrossRefPubMedGoogle Scholar
  122. 122.
    Willoughby SJ, Fairhead S, Woodcock BE, Pearson TC. Postpartum thrombosis in primary thrombocythaemia. Eur J Haematol. 1997;59(2):121–123. Accessed 19 Apr 2015.
  123. 123.
    Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol. 2005;61(12):899–906. doi: 10.1007/s00228-005-0055-1.CrossRefPubMedGoogle Scholar
  124. 124.
    Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med. 2009;360(24):2528–35. doi: 10.1056/NEJMoa0807154.CrossRefPubMedGoogle Scholar
  125. 125.
    Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 2012;94(1):22–30. doi: 10.1002/bdra.22865.PubMedCentralCrossRefPubMedGoogle Scholar
  126. 126.
    Tincello DG, Johnstone MJ. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). Postgrad Med J. 1996;72(853):688–689. Accessed 19 Mar 2015.
  127. 127.
    Pasternak B, Svanström H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368(9):814–23. doi: 10.1056/NEJMoa1211035.CrossRefPubMedGoogle Scholar
  128. 128.
    Andersen JT, Jimmenez-Solem E, Andersen NL. Ondansetron use in early pregnancy and the risk of congenital malformations. Int Soc Pharmacoepidemiol. 2013 (Abstract 25, Pregnancy session 1.).Google Scholar
  129. 129.
    Koren G. Treating morning sickness in the United States–changes in prescribing are needed. Am J Obstet Gynecol. 2014;211(6):602–6. doi: 10.1016/j.ajog.2014.08.017.CrossRefPubMedGoogle Scholar
  130. 130.
    Calhoun DA, Rosa C, Christensen RD. Transplacental passage of recombinant human granulocyte colony-stimulating factor in women with an imminent preterm delivery. Am J Obstet Gynecol. 1996;174(4):1306–1311. Accessed 22 Nov 2014.
  131. 131.
    Okasaki K. Twenty-six-week repeat-dose toxicity study of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim) in cynomolgus monkeys. Toxicol Sci. 2002;65(2):246–55. doi: 10.1093/toxsci/65.2.246.CrossRefPubMedGoogle Scholar
  132. 132.
    Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol. 15(6):637–646. Accessed 19 Mar 2015.
  133. 133.
    Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol. 2010;33(3):221–8. doi: 10.1097/COC.0b013e3181a44ca9.PubMedGoogle Scholar
  134. 134.
    Sorosky JI, Sood AK, Buekers TE. The use of chemotherapeutic agents during pregnancy. Obstet Gynecol Clin N Am. 1997;24(3):591–599. Accessed 22 Nov 2014.
  135. 135.
    Amant F, Van Calsteren K, Halaska MJ, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer. 2009;19(Suppl 1):S1–12. doi: 10.1111/IGC.0b013e3181a1d0ec.CrossRefPubMedGoogle Scholar
  136. 136.
    Backes CH, Moorehead PA, Nelin LD. Cancer in pregnancy: fetal and neonatal outcomes. Clin Obstet Gynecol. 2011;54(4):574–90. doi: 10.1097/GRF.0b013e318236e8d9.CrossRefPubMedGoogle Scholar
  137. 137.
    Tyson JE, Parikh NA, Langer J, Green C, Higgins RD. Intensive care for extreme prematurity–moving beyond gestational age. N Engl J Med. 2008;358(16):1672–81. doi: 10.1056/NEJMoa073059.PubMedCentralCrossRefPubMedGoogle Scholar
  138. 138.
    Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet. 2012;379(9815):570–9. doi: 10.1016/S0140-6736(11)61092-1.CrossRefPubMedGoogle Scholar
  139. 139.
    Han SN, Kesic VI, Van Calsteren K, Petkovic S, Amant F. Cancer in pregnancy: a survey of current clinical practice. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):18–23. doi: 10.1016/j.ejogrb.2012.10.026.CrossRefPubMedGoogle Scholar
  140. 140.
    Cancer survivors–United States, 2007. MMWR Morb Mortal Wkly Rep. 2011;60(9):269–272. Accessed 22 Nov 2014.
  141. 141.
    Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34(4):302–12. doi: 10.1016/j.ctrv.2008.01.002.CrossRefPubMedGoogle Scholar
  142. 142.
    Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7(2):122–192. Accessed 22 Nov 2014.

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Hematology and Bone Marrow Transplant UnitTel Aviv Medical CenterTel AvivIsrael

Personalised recommendations